Evidence map›Paper›PMID 24911462›Full record

ReviewJournal of hepatology2014

Vascular pathobiology in chronic liver disease and cirrhosis - current status and future directions.

Yasuko Iwakiri, Vijay Shah, Don C Rockey

Open access · bronzeAbstract readReview
In one paragraph

Review in Journal of hepatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 135 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
135citing papers in PubMed, 3 pooled it
10.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

135 citing papers in PubMed, 3 syntheses or guidelines pooled it, 300 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Actin cytoskeletal dynamics in hepatic myofibroblasts and fibrosis.Nature reviews. Gastroenterology & hepatology · 2026
    Review
  6. Article
  7. Article
  8. Lumped parameter modeling of changes in liver hemodynamics due to cirrhosis.Biomechanics and modeling in mechanobiology · 2026
    Article
  9. Article
  10. Article
  11. Clinical feasibility of accelerated whole liver water TEuropean radiology experimental · 2026
    Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Liver macrophages: development, dynamics, and functions.Cellular & molecular immunology · 2025
    Review
  17. Review
  18. Review
  19. Review
  20. Article

75 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Yasuko IwakiriThe Section of Digestive Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, United States.
Vijay ShahThe Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, United States.
Don C RockeyThe Department of Medicine, Medical University of South Carolina, Charleston, SC, United States. Electronic address: rockey@musc.edu.
Mayo Clinic in Arizona · USMedical University of South Carolina · USYale University · US

Funding

Mayo Clinic Center for Translational Science ActivitiesUL1TR000135 · NCATS · MAYO CLINIC ROCHESTER · PI KHOSLA, SUNDEEP · 2012 to 2015
$41.2M
Molecular Mechanisms of Portal HypertensionR01DK059615 · NIDDK · MAYO CLINIC ROCHESTER · PI SHAH, VIJAY H. · 2002 to 2023
$6.4M
NO AND THE CELLULAR PATHOGENESIS OF PORTAL HYPERTENSIONR01DK057830 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI ROCKEY, DON C. · 2000 to 2012
$2.6M
Arterial Remodeling in Chronic Liver DiseasesR01DK082600 · NIDDK · YALE UNIVERSITY · PI IWAKIRI, YASUKO · 2009 to 2014
$2.0M
NCATS NIH HHS UL1 TR000135NIDDK NIH HHS R01 DK057830NIDDK NIH HHS R01 DK059615NIDDK NIH HHS R01 DK082600NIDDK NIH HHS R01DK082600NIDDK NIH HHS R01DK57830NIDDK NIH HHS R01DK59615
6 · The paper itself

Abstract

Chronic liver disease is associated with remarkable alterations in the intra- and extrahepatic vasculature. Because of these changes, the fields of liver vasculature and portal hypertension have recently become closely integrated within the broader vascular biology discipline. As developments in vascular biology have evolved, a deeper understanding of vascular processes has led to a better understanding of the mechanisms of the dynamic vascular changes associated with portal hypertension and chronic liver disease. In this context, hepatic vascular cells, such as sinusoidal endothelial cells and pericyte-like hepatic stellate cells, are closely associated with one another, where they have paracrine and autocrine effects on each other and themselves. These cells play important roles in the pathogenesis of liver fibrosis/cirrhosis and portal hypertension. Further, a variety of signaling pathways have recently come to light. These include growth factor pathways involving cytokines such as transforming growth factor β, platelet derived growth factor, and others as well as a variety of vasoactive peptides and other molecules. An early and consistent feature of liver injury is the development of an increase in intra-hepatic resistance; this is associated with changes in hepatic vascular cells and their signaling pathway that cause portal hypertension. A critical concept is that this process aggregates signals to the extrahepatic circulation, causing derangement in this system's cells and signaling pathways, which ultimately leads to the collateral vessel formation and arterial vasodilation in the splanchnic and systemic circulation, which by virtue of the hydraulic derivation of Ohm's law (pressure = resistance × flow), worsens portal hypertension. This review provides a detailed review of the current status and future direction of the basic biology of portal hypertension with a focus on the physiology, pathophysiology, and signaling of cells within the liver, as well as those in the mesenteric vascular circulation. Translational implications of recent research and the future directions that it points to are also highlighted.

Indexed as

Hypertension, PortalLiverSignal TransductionEndothelial CellsHemodynamicsHepatic Stellate CellsHumansLiver CirculationLiver CirrhosisNeovascularization, PathologicPortal SystemTranslational Research, BiomedicalVascular ResistanceEndothelial cellPericytePressureResistanceSinusoidTherapy

Identifiers

PMID24911462
PMCPMC4346093
OpenAlexW1968333663

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.